News

Topline Data Expected in 2Q 2023. SEATTLE, Wash. and VANCOUVER, British Columbia, Feb. 7, 2023 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the final subject of the Company’s Phase 2 ORCA-V1 trial…

Topline Results Remain on Schedule to be Reported in the Second Quarter of 2023. SEATTLE, Wash. and VANCOUVER, British Columbia, January 9, 2023 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the final…

SEATTLE, Wash and VANCOUVER, British Columbia, November 8, 2022 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for nicotine dependence, today announced that target enrollment has been reached in the Phase 2 ORCA-V1 clinical trial. ORCA-V1 is evaluating the efficacy and safety…

ORCA-3 Designed to Enable FDA Registration and Confirm the Efficacy and Safety of 3 mg Cytisinicline Three Times Daily Dosing Compared to Placebo in Adult Smokers in the United States. SEATTLE, Wash and VANCOUVER, British Columbia, September 27, 2022 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization…

SEATTLE and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it has initiated screening of subjects for the ORCA-V1 Phase 2 clinical trial. ORCA-V1 will evaluate the…